Arcus Biosciences (RCUS) opened 2026 with Q1 revenue of US$17 million and a basic EPS loss of US$1.02, alongside a net loss of US$128 million, as investors weigh how the current burn supports its pipeline progress. Over recent quarters the company has seen quarterly revenue move from US$28 million in Q1 2025 to US$160 million in Q2 2025, before settling at US$33 million in Q4 2025 and US$17 million in Q1 2026. Over the same period, EPS has ranged between a loss of US$0.89 and US$1.27 per share, setting up a story that is as much about spending discipline and margins as it is about top line scale.

See our full analysis for Arcus Biosciences.

With the latest figures on the table, the next step is to see how these results line up with the prevailing bull and bear narratives around Arcus Biosciences, and where the numbers start to push back on those stories.

Losses Stay Heavy With US$369 Million LTM Net Loss

• On a trailing twelve month basis to Q1 2026, Arcus reported total revenue of US$236 million against a net loss of US$369 million and a basic EPS loss of US$3.23.
• Critics highlight the bearish view that continued high R&D spend and dependency on partners could keep earnings under pressure, and the recent figures underline that tension:
  • Quarterly net loss moved from US$94 million in Q4 2024 to US$128 million in Q1 2026 while revenue over that span ranged between US$17 million and US$33 million outside the Q2 2025 spike. Losses therefore remain large relative to the current revenue base.
  • The bearish narrative also points to rising development costs and a concentrated late stage pipeline. The absence of any profitable quarter in the recent history provided leaves that concern intact rather than clearly countered by the latest numbers.

Stay with this cautious frame in mind and see how skeptics think the story could play out from here 🐻 Arcus Biosciences Bear Case.

DCF Fair Value Points To Large Upside Tension

• With the stock at US$26.00 and a stated DCF fair value of US$161.60, Arcus is described as trading about 83.9% below that modelled value while also on a P/S of 13.9x versus 10.8x for the US Biotechs industry and 18.4x for peers.
• What stands out for the bullish narrative is the mix of strong revenue expectations and this valuation gap, yet the loss profile keeps the case complex:
  • Bullish analysts highlight forecast revenue growth of about 37.9% per year, and the trailing twelve month revenue of US$236 million provides a base that supporters link to that growth story, even though the company still recorded a US$369 million loss over the same period.
  • At the same time, the current P/S of 13.9x is higher than the broader biotech group but below peers. Bulls can read this as some recognition of growth potential, while bears point to continued unprofitability and shareholder dilution over the last year as reasons to question how quickly any perceived discount to DCF fair value might close.

If you want to see how optimistic investors connect this valuation gap to future growth, it is worth reading their case 🐂 Arcus Biosciences Bull Case.

Revenue Volatility Versus 37.9% Growth Forecast

• Quarterly revenue swung from US$160 million in Q2 2025 to US$17 million in Q1 2026, yet over the last 12 months revenue totaled US$236 million and is linked to a forecast growth rate of about 37.9% per year.
• Consensus narrative focuses on casdatifan and other late stage programs as key drivers for future revenue, and the current pattern of numbers both supports and complicates that view:
  • Across the last five reported quarters, revenue outside the Q2 2025 spike ranged between US$17 million and US$33 million while trailing twelve month revenue peaked at US$262 million in Q2 2025 then sat at US$236 million by Q1 2026. The current base that future oncology launches would build on is therefore still relatively modest.
  • Analysts also highlight that Arcus is expected to remain loss making for at least the next three years, and with trailing twelve month EPS at a loss of US$3.23, the idea that late stage trials can eventually support earnings growth sits alongside a present reality of sizeable ongoing losses.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Arcus Biosciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

The mix of heavy losses, a wide DCF gap and a split bull bear narrative leaves plenty of room for your own judgment, so move quickly from the headline numbers and see the 2 key rewards and 2 important warning signs

See What Else Is Out There

Arcus Biosciences is still posting sizeable losses relative to its US$236 million revenue base, with no profitable quarter in the recent data provided.

If you want stocks where the balance between earnings, revenue and risk looks more comfortable, start comparing ideas using the 74 resilient stocks with low risk scores today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.